STOCK TITAN

Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced advancements in producing its ImmCelz® product, achieving higher volumes in under 72 hours through a novel cell-free supercharging solution. This method consistently maintains the potency of ImmCelz®, which uses adult stem cells to enhance immune response. The company is focusing on stroke first, seeking FDA approval for clinical trials. Future applications may address Type I diabetes, heart, liver, and kidney diseases, signaling strong potential for improving patient outcomes.

Positive
  • Demonstrated ability to produce ImmCelz® in under 72 hours, enhancing production efficiency.
  • Consistent potency confirmed across multiple clinical experiments.
  • Focus on stroke as initial indication with plans for FDA clinical trials.
Negative
  • None.

-- Initial experiments demonstrate expeditious potential for high-volume production of ImmCelz® with consistent potency --

PHOENIX, April 20, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced progress in developing a reproducible clinical grade product of ImmCelz®. Multiple clinical experiments were performed in which the ImmCelz® product was produced in less than 72 hours, utilizing the Company's cell-free supercharging solution. The amount of ImmCelz® produced was significantly greater than the control in numerous replicates of the experiments. There was also the ability to verify repeated potency of the final ImmCelz® product.

Timothy Warbington, President and CEO of the Company, commented, "We are excited to receive this great news, which further validates our immunotherapy platform and sets the stage for advancing clinical studies.  We look forward to continuing to work closely with team members at the University of Miami who bring decades of combined experience to our projects. We believe that our Immcelz® program has enormous potential to improve outcomes for patients across multiple indications, including stroke, Type I diabetes, heart disease, liver disease, and kidney disease."

About ImmCelz®

ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to endow specific properties to the patient's immune cells. After the patient's harvested cells are incubated with the Company's cell-free reprogramming "cocktail", the cells are re-injected back into the patient. These "supercharged" cells subsequently "educate" other cells of the immune system to stop attacking the body, while preserving the ability to attack foreign pathogens.

The Company plans to advance multiple indications for ImmCelz® starting with stroke, which is currently under FDA review. Upon successful approval to proceed with clinical trials for stroke, the Company anticipates accelerating additional therapies under the ImmCelz® umbrella, including for Type I diabetes, heart disease, liver disease, and kidney disease.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of immunotherapy, urology, neurology, and orthopedics. For further information about the Company, please visit www.creativemedicaltechnology.com

Forward Looking Statements

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

Company Contact


Investor Relations




Creative Medical Technology


The Equity Group Inc.

IR@CreativeMedicalTechnology.com


Kalle Ahl, CFA






(212) 836-9614



kahl@equityny.com






Devin Sullivan



(212) 836-9608



dsullivan@equityny.com

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-announces-progress-in-developing-a-reproducible-clinical-grade-of-the-companys-immcelz-product-301528924.html

SOURCE Creative Medical Technology Holdings, Inc.

FAQ

What recent progress has Creative Medical Technology made with ImmCelz®?

Creative Medical Technology announced significant advancements in producing ImmCelz®, achieving high volume production in less than 72 hours.

How does ImmCelz® work?

ImmCelz® utilizes adult stem cells from qualified donors, reprogramming the patient's immune cells to enhance their response.

What indications will ImmCelz® target?

The initial focus will be on stroke, with future plans to address Type I diabetes, heart disease, liver disease, and kidney disease.

When will Creative Medical Technology begin clinical trials for ImmCelz®?

The company is currently seeking FDA approval to start clinical trials for stroke.

What is the significance of the cell-free supercharging solution for ImmCelz®?

This solution allows for faster production of ImmCelz® while maintaining its potency, enhancing the product's efficiency.

Creative Medical Technology Holdings, Inc.

NASDAQ:CELZ

CELZ Rankings

CELZ Latest News

CELZ Stock Data

3.74M
1.71M
2.1%
3.96%
2.22%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
PHOENIX